Effectiveness, safety, and quality of life outcomes of teduglutide treatment in adult patients with short bowel syndrome-associated intestinal failure: A systematic literature review of real-world studies Authors: Shirley C Paski, Anja Becher, Pradeep Nazarey, Kishore Iyer Published: 2026 ABSTRACT AbstractBackgroundShort bowel syndrome-associated intestinal failure (SBS-IF) results from a reduction in the small intestine length, leading to parenteral nutrition and/or intravenous fluids (PN/IV) dependence. Teduglutide can reduce reliance on PN/IV. Previous teduglutide systematic reviews are limited, including only data from studies suitable for meta-analysis. Here, we aim to summarize the broader literature describing the real-world outcomes of adults with SBS-IF.MethodsWe conducted a systematic literature review in the Ovid Embase and MEDLINE databases to April 9, 2024, to identify publications reporting effectiveness, health-related quality of life (HRQoL), and/or safety of teduglutide in adults with SBS-IF in real-world clinical practice. Key conference proceedings were also searched.ResultsOf 645 publications identified, 31 publications describing 26 unique real-world studies were included. The number of patients per study ranged from 6 to 669. All 13 studies presenting infusion frequency reported an improvement with teduglutide. In total, 21/22 studies reporting PN/IV volume observed improvement with teduglutide. Patient proportion attaining enteral autonomy ranged from 10.5% to 100% at the last time point reported (21 studies). Teduglutide showed effectiveness across anatomic groups. Improvements were observed in four studies reporting HRQoL. Safety was reported in 17 studies; the most frequently reported adverse events included abdominal pain/cramping, nausea, injection-site reactions, catheter-related sepsis/infection, and stoma complications.ConclusionThis systematic review summarizes 10 years of real-world evidence on the effectiveness, including HRQoL, and safety of teduglutide in treating adults with SBS-IF in clinical practice, across phenotypic anatomic groups including patients with stomas and patients with colon in continuity.Keywords: Parenteral nutrition, Short bowel syndrome, Teduglutide Introduction Short bowel syndrome (SBS) is a malabsorptive disorder resulting from extensive intestinal resection or diseases of the small intestine and is the main cause of chronic intestinal failure (IF) [1], [2]. Individuals with SBS-associated IF (SBS-IF) cannot absorb sufficient nutrients or fluids and require parenteral nutrition and/or intravenous fluids (PN/IV) [3], [4]. Use of PN/IV can cause complications, such as infections [3]; higher volumes and a greater frequency of PN/IV can worsen health-related quality of life (HRQoL) [4], [5], [6]. Having part or all of the colon in continuity (CIC) has been shown to be associated with improved intestinal absorption capacity and better outcomes in patients with SBS-IF [7], [8]. In clinical trials of adult patients with SBS-IF, the glucagon-like peptide−2 analog, teduglutide, has been shown to reduce PN/IV requirements and improve HRQoL [9], [10], [11], [12], [13], [14]. Post hoc analysis found greater PN/IV volume reduction in patients with jejunostomy or ileostomy than for those with at least 50% CIC and no stoma [15]. Patient characteristics in real-world clinical practice may differ from those in clinical trials, which often have narrow study eligibility criteria [16]. The effectiveness of teduglutide in clinical practice has been assessed in systematic reviews in 2020 and 2021 [17], [18], while safety was assessed in a 2025 review [19]; all included only studies suitable for meta-analysis. Expanding on previous analyses to include a broader range of outcomes and updating the literature search can provide comprehensive insights into the real-world effectiveness and safety of teduglutide in adult patients with SBS-IF, including improvements in HRQoL – an ever-important goal in the management of SBS-IF [4]. This systematic literature review (SLR) summarizes the real-world outcomes of teduglutide treatment in adult patients with SBS-IF. Materials and methods Study registration and reporting The SLR protocol was prospectively registered with the International Prospective Register of Systematic Reviews (PROSPERO) on June 10, 2024, before data extraction (PROSPERO registration ID: CRD42024554503). Reporting followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [20]. Eligibility criteria Eligible studies were real-world studies reporting specified effectiveness outcomes, HRQoL, and/or safety of teduglutide in adults with SBS-IF that included five or more patients with SBS-IF who received teduglutide; and, for effectiveness outcomes (including HRQoL), studies that reported changes in outcome(s) from baseline to post-baseline time point(s) or provided data for these changes to be calculated (see Supplementary Table S1 for predefined inclusion criteria based on population, intervention/comparator, outcomes, and study design [PICOS]). No language restrictions were implemented. Clinical trials were excluded. Data sources and search strategy A systematic literature search was conducted in the Ovid Embase and Ovid MEDLINE databases on April 9, 2024 (see Supplementary Table S2 for search strategy). The search terms were “teduglutide”, “Revestive”, “Gattex”, “ALX0600”, “ALX 0600”, “glucagon-like peptide−2 analog”, and “glucagon-like peptide−2 analogue”. No date limits were implemented for full publications. The conference search was limited to the past 2 years and included congresses of the American College of Gastroenterology, American Society for Parenteral and Enteral Nutrition, Congress of the Intestinal Rehabilitation and Transplant Association (congress name at the time of searches), Digestive Disease Week, European Society for Clinical Nutrition and Metabolism, and United European Gastroenterology Week. Study screening Following the systematic literature search, identified publications were screened based on title, abstract, and/or full text to determine eligibility. Two reviewers independently assessed the results using a double-blind approach. Disagreements were resolved via discussion to arrive at consensus. Studies not meeting the eligibility criteria were excluded. Data extraction Data extracted included publication and study details; baseline patient demographics and clinical characteristics; effectiveness variables (including HRQoL) at baseline and follow-up; change in effectiveness variables (including HRQoL) from baseline to follow-up time point(s); medication burden; dose changes, interruptions, and discontinuations; and safety. The primary outcome was change in PN/IV infusion frequency (days per week) from baseline to follow-up time point(s). Secondary outcomes were change in PN/IV volume per week from baseline to follow-up time point(s); proportion attaining enteral autonomy; change in HRQoL from baseline to follow-up time point(s); change in medication burden from baseline to follow-up time point(s); dose changes, interruptions, and discontinuations during follow-up; and safety during follow-up. A single researcher extracted the data using a standardized form that was then cross-checked against the source data by a second researcher in a single-blind approach. Risk of bias assessment The Risk of Bias in Non-randomized Studies of Interventions (ROBINS-I) tool, used to evaluate risk of bias in nonrandomized studies, was selected to assess the risk of bias (quality) of included studies [21]. Risk of bias assessments were conducted by the authors; discrepancies were resolved by consensus. Data analysis Studies reporting PN and IV data separately are listed individually in the tables and as PN/IV in the summary text. Included studies were grouped by outcomes for narrative synthesis. Absolute differences versus baseline were reported for each study. The direction of effect was assessed for consistency by vote counting (as described in McKenzie and Brennan [22]). In addition, data for PN/IV-related outcomes were inspected across studies in relation to follow-up time and study size. Results Search results The systematic literature search identified 628 and 302 publications from Ovid Embase and Ovid MEDLINE, respectively (Fig. 1). Removal of duplicates resulted in a total of 645 publications for screening: 57 abstracts and 588 full publications. Screening by title, abstract, and/or full text yielded 31 publications for inclusion: 22 full papers and nine congress presentations [23], [24], [25], [26], [27], [28], [29], [30], [31], [32], [33], [34], [35], [36], [37], [38], [39], [40], [41], [42], [43], [44], [45], [46], [47], [48], [49], [50], [51], [52], [53]. The included publications together described 26 real-world studies of teduglutide in SBS-IF. The most common reasons for exclusion were that the publication was a review, commentary, or guidance (n = 362), that it was presenting preclinical data (n = 74), or that it was based on clinical trial data (n = 55; Fig. 1). PRISMA flow chart of the systematic literature search. PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses. Eight publications included overlapping patient populations and were grouped, as follows: three publications reporting single-center data in France [27], [28], [42], three publications reporting on the multinational SBS Registry [30], [36], [44], and two publications reporting on an Argentinian single-center database [31], [51] (Table 1). The French single-center study contributed patient data to a French multicenter study [35], [42]; these studies are listed separately, but with the overlap noted (Table 1). Table 1Overview of included studies.Country and publicationStudy typeStudy periodN who received teduglutideAge, yearsaFemale, %Prior PN/IV duration, yearsaRemaining small bowel length, cmaCIC, %ArgentinaGondolesi 2020 [31]Single-center database (overlapping populations)2006–20188––––b–Solar 2021 [51]2006–20201740476.538c94.1Solar-Muñiz 2023 [52]NR2020–2023d16–––––AustraliaChapman 2023 [24]Single center2018–20231050e708.1e––AustriaHarpain 2022 [33]Single center2016–2020135115–7377CanadaDaoud 2023 [26]Registry2015 – ≥ 20213458597.0e60e44CzechiaOuradova 2023 [43]Registry2021–NR33–––––FranceDe Dreuille 2023 [28]Single center (overlapping populations)2015–20205650e462.2e68e64De Dreuille 2023 [27]2009–202235 f4740–7466Martin 2021 [42]2009–201931 g51e35–74e52Joly 2020 [35]Multicenter2015–201754 h52359.86265GermanyBlüthner 2023 [23]Single center2014–20221748531.3e7788Greif 2022 [32]Multicenter2014–202052i4958–80e37jPevny 2019 [45]Multicenter2014–NR27k51524.3CIC: 45Stoma: 20578Schoeler 2018 [49]Single center–1449 l64 l3.8 l65 l64 lItalyPira 2023 [46]Single center2019–NR10––––40JapanSato 2023 [48]Single center2020–202116 m49e3810.5e143e31SlovakiaGombošová 2024 [29]Multicenter2020–2022947443.857–SpainMaiz Jimenez 2023 [41]MulticenterNR–2022315135–88c58United StatesCompher 2016 [25]Single center2006–20137 n6257 l––b43Iyer 2023 [34]Claims data2018–202120–––––Kim 2024 [37]Single center2012–2022135869≥ 0.5–15°Kochar 2017 [38]Multicenter2007–2014135269–––Lam 2018 [39]Single center2009–201518p47e613e55e83Loutfy 2022 [40]Commercial database2015–2019170–71–––Puello 2021 [47]Single center2013–201918q54e563.3e100e50Siu 2024 [50]Single center2012–20233261e66–––Ukleja 2018 [53]Single center2013–2016646674.67550MultinationalGondolesi 2023 [30]SBS Registry (NCT01990040; overlapping populations)2014–20226695459–8420Joly 2023 [36]2014–20215405660–––Pape 2023 [44]2014–2021362––≥ 0.5––All applicable information was reported if available. Values may have been rounded for consistency in reporting. Cells containing only dashes indicate that the information was not reported.CIC, colon in continuity; NR, not reported; PN/IV, parenteral nutrition and/or intravenous fluids; SBS, short bowel syndrome.aMean unless otherwise indicated.bNot reported consistently.cIntestinal length.dInformation obtained from study record on ClinicalTrials.gov (NCT04877431).eMedian.fOnly patients who underwent follow-up endoscopy were included in the study.gOnly patients with available computed tomography data were included in the study.hOf whom 21 were also included in Martin et al. [42].iOf whom 49 were receiving PN/IV.j≥ 50% CIC and no stoma.kOf whom 19 patients were analyzed.lCalculated from source.mTwo additional patients who discontinued within 8 weeks were not included in the study’s analysis.nTwo as part of clinical trial.oIntact colon.pFive patients continuing from a clinical trial.qOne additional patient stopped therapy after 1 month because of gastrointestinal obstruction and was not included in the analysis. Overview of included studies. All applicable information was reported if available. Values may have been rounded for consistency in reporting. Cells containing only dashes indicate that the information was not reported. CIC, colon in continuity; NR, not reported; PN/IV, parenteral nutrition and/or intravenous fluids; SBS, short bowel syndrome. Mean unless otherwise indicated. Not reported consistently. Intestinal length. Information obtained from study record on ClinicalTrials.gov (NCT04877431). Median. Only patients who underwent follow-up endoscopy were included in the study. Only patients with available computed tomography data were included in the study. Of whom 21 were also included in Martin et al. [42]. Of whom 49 were receiving PN/IV. ≥ 50% CIC and no stoma. Of whom 19 patients were analyzed. Calculated from source. Two additional patients who discontinued within 8 weeks were not included in the study’s analysis. Two as part of clinical trial. Intact colon. Five patients continuing from a clinical trial. One additional patient stopped therapy after 1 month because of gastrointestinal obstruction and was not included in the analysis. Study characteristics Table 1 provides an overview of the 26 included studies, which were conducted at various geographical locations. The number of teduglutide-treated patients per study ranged from six, in a single-center study conducted in the USA [53], to 669, in the multinational SBS Registry [30]. The reported average (mean or median) age of teduglutide-treated patients ranged from 40 years to 62 years across the studies. Between 15% and 71% of participants were women; the lowest proportion of women was reported in an Austrian single-center study [33], whereas the highest proportion was reported in a US commercial database [40]. Most studies that reported on sex distribution (15/22) included more women than men. Prior PN/IV duration ranged from at least 0.5 years to a median of 10.5 years. Twenty studies reported the causes of SBS-IF; inflammatory bowel disease, mesenteric ischemia, surgical complications, and traumatic injury were the most common causes. Three studies included only patients with Crohn’s disease (CD) as the cause of their SBS-IF [38], [48], [51]. Nineteen studies reported the proportion of patients with CIC, which ranged from 15% to 88% across the studies (Table 1). Infusion frequency Infusion frequency was reported for PN/IV in five studies, for PN and IV separately in three studies, and for PN only in five studies (Table 2). Overall, the reported follow-up time points ranged from 12 weeks to 5 years; seven studies included more than one follow-up time point. All 13 studies observed a reduction (improvement) in infusion frequency. The observed change in infusion frequency ranged from −0.3 days/week in a German multicenter study (at 12 weeks) [45] to −6.1 days/week (at 5 years) in a US single-center study [47]. Table 2PN/IV infusion frequency at baseline and follow-up.PublicationN who received teduglutideBaseline infusion frequency, days/weekaFollow-up time point(s)Parameter assessedFollow-up infusion frequency, days/weekaChange from baseline in infusion frequency, days/weekaBlüthner 2023 [23]176 (SD: 1)4.3 yearsbPN2.7c–3.3 (p < 0.001)Compher 2016 [25]75.3cNRPN3.7c–1.6cDaoud 2023 [26]345.0b (IQR: 3.5–7.0)6 monthsPN/IV4.0b,c–1.0b (IQR: 0.0–2.0)12 monthsPN/IV3.5b,c–1.5b (IQR: 0.0–3.0)18 monthsPN/IV2.5b,c–2.5b (IQR: 1.0–4.0)Gombošová 2024 [29]9PN: 5.9 (SD: 1.8)IV: 6.1 (SD: 1.0)12 weeksPN4.3 (SD: 1.9)–1.6 (SD: 1.9)IV5.5 (SD: 1.5)–0.6 (SD: 1.1)6 monthsPN2.4 (SD: 1.5)–3.5 (SD: 1.9)IV4.3 (SD: 2.2)–1.9 (SD: 1.6)Greif 2022 [32]527.0b (range: 1.0–7.0)3 monthsPN4.5b (range: 1.0–7.0)–2.5b,c6 monthsPN4.5b (range: 0.0–7.0)–2.5b,c (p < 0.01)12 monthsPN5.0b (range: 0.0–7.0)–2.0b,c (p < 0.001)Joly 2020 [35]544.4 (SD: 0.2)24 weeksPN/IV2.9c–1.5 (SD: 0.2)Martin 2021 [42]314.0b (IQR: 3.0–5.0)12 monthsPN/IV2.0b (IQR: 0.0–4.0)–2.0b,c (p < 0.001)Pevny 2019 [45]27PN: 5.4IV: 3.912 weeks(n = 19)dPN4.5–0.9c (p = 0.008)IV3.6–0.3c (p = 0.469)PN: 5.6IV: 4.424 weeks(n = 17)dPN4.3–1.3c (p = 0.001)IV3.9–0.5c (p = 0.422)PN: 5.9IV: 3.652 weeks(n = 11)dPN3.6–2.3c (p = 0.002)IV3.1–0.5c (p = 0.750)PN: 5.5IV: 3.278 weeks(n = 8)dPN3.4–2.1c (p = 0.008)IV2.7–0.5c (p = 1.000)PN: 5.3IV: 2.6104 weeks(n = 7)dPN3.0–2.3c (p = 0.016)IV2.1–0.5c (p = 1.000)Puello 2021 [47]186.1 (95% CI: 5.2–6.9)3 months (n=18)PN/IV4.3 (95% CI: 3.1–5.6)–1.8c6 months (n= 18)PN/IV3.9 (95% CI: 2.6–5.3)–2.2c12 months (n= 16)PN/IV3.9 (95% CI: 2.6–5.3)–2.2c24 months (n = 13)PN/IV3.5 (95% CI: 1.8–5.1)–2.6c36 months (n = 10)PN/IV3.9 (95% CI: 1.8–6.0)–2.2c60 months (n = 3)PN/IV0.0 (95% CI: 0.0–0.0)–6.1cSchoeler 2018 [49]145.648 weeks (n = 10)PN/IV4.2c–1.4e> 12 months (n = 7)PN/IV2.0c–3.6 (p < 0.05)Siu 2024 [50]32PN: 7.0b (IQR: 3.9–7.0);IV: 7.0b (IQR: 3.0–7.0)–PN3.0b (IQR: 0.0–7.0)–4.0b,c (p < 0.01)IV3.0b (IQR: 0.0–7.0)–4.0b,c (p < 0.01)Solar 2021 [51]175.2 (SD: 1.3)–PN2.7 (SD: 1.6)–2.5cSolar-Muñiz 2023 [52]164.5b (IQR: 4.0–7.0)12 weeksPN4b (IQR: 4–5)–0.5b,c (p < 0.01)24 weeksPN3b (IQR: 0–4)–1.5b,c (p < 0.01)All applicable information was reported if it was available or could be calculated from source data. Values may have been rounded for consistency in reporting. Cells containing only dashes indicate that the information was not available and could not be calculated.CI, confidence interval; IQR, interquartile range; IV, intravenous fluids; PN, parenteral nutrition; PN/IV, parenteral nutrition and/or intravenous fluids; SD, standard deviation.aMean unless otherwise indicated.bMedian.cCalculated from source.dValues are for patients with corresponding follow-up data.eP value not statistically significant; actual value not reported. PN/IV infusion frequency at baseline and follow-up. All applicable information was reported if it was available or could be calculated from source data. Values may have been rounded for consistency in reporting. Cells containing only dashes indicate that the information was not available and could not be calculated. CI, confidence interval; IQR, interquartile range; IV, intravenous fluids; PN, parenteral nutrition; PN/IV, parenteral nutrition and/or intravenous fluids; SD, standard deviation. Mean unless otherwise indicated. Median. Calculated from source. Values are for patients with corresponding follow-up data. P value not statistically significant; actual value not reported. In studies that included more than one follow-up time point, reductions from baseline were generally greater over time. Across studies reporting changes in PN/IV infusion frequency, mean/median change values ranged from −1.0 to –2.2, –1.5 to –2.2, and –2.2 to –6.1 days/week, at 6, 12, and/or > 12 month follow-ups, respectively. No consistent patterns were observed in relation to cohort size. Infusion volume Twenty-two studies reported on change in weekly PN/IV volume from baseline to follow-up time points (4 weeks to 5 years; Table 3). Twenty-one studies observed a reduction (improvement) in weekly PN/IV volume; the change in PN/IV volume ranged from −0.3 L/week (at 4 weeks) in the Argentinian single-center database study [51] to −9.9 L/week (at 5 years) in a US single-center study [47]. An increase of 0.4 L/week in weekly PN/IV volume was reported by one study [25]. Table 3PN/IV volume at baseline and follow-up.PublicationN who received teduglutideBaseline infusion volume, L/weekaFollow-up time point(s)Parameter assessedFollow-up infusion volume, L/weekaChange from baseline in infusion volume, L/weekaBlüthner 2023 [23]1713.9 (SD: 6.6)4.3 yearsbPN/IV6.3c−7.6 (p < 0.001)Chapman 2023 [24]1010.8b12–48 monthsPN/IV5.5b−5.3b,c (p < 0.01)Compher 2016 [25]712.5cNRPN12.9c+0.4cDaoud 2023 [26]3410.8b (IQR: 7.0–14.7)6 monthsPN/IV9.4b,c−1.4b (IQR: −0 to −4.1)12 monthsPN/IV8.0b,c−2.8b (IQR: −1.0 to −6.0)18 monthsPN/IV8.0b,c−2.8b (IQR: −1.0 to −9.1)De Dreuille 2023 [28]568.8b (IQR: 5.0–12.5)2.7 yearsbPN/IV5.3b,c−3.5b,cGombošová 2024 [29]97.9 (SD: 3.9)12 weeksIV5.5 (SD: 4.4)−2.4 (SD: 1.2) (p = 0.023)6 monthsIV3.4 (SD: 2.4)−4.4 (SD: 2.1) (p = 0.013)Greif 2022 [32]5213.4 (SD: 7.5)3 monthsPN/IV11.9 (SD: 7.3)−1.5c6 monthsPN/IV10.9 (SD: 6.8)−2.5c (p < 0.01)12 monthsPN/IV9.6 (SD: 6.7)−3.8c (p < 0.001)Joly 2020 [35]5411.2 (SD: 1.1)24 weeksPN/IV6.3c−4.9 (SD: 0.6)Kochar 2017 [38]139.0b (IQR: 7.0–14.0)14 monthsbIV5.9c–3.1b (IQR: −2.4 to −8.4)Lam 2018 [39]189.9b (range: 2.7–30)NRPN/IV4.5c–5.4b (range: –0 to –16.8)Maiz Jimenez 2023 [41]3110.9(range: 4.5–35.1)6 monthsPN/IV5.5c–5.4c1 yearPN/IV3.9c–7.0c2 yearsPN/IV3.7c–7.2c3 yearsPN/IV3.5c–7.4c4 yearsPN/IV3.2c–7.7cMartin 2021 [42]317.5b (IQR: 3.5–15.0)12 monthsPN/IV3.6b (IQR: 0–7.5)–3.9b,c (p < 0.001)Ouradova 2023 [43]336.8c6 monthsIV2.1c–4.7Pape 2023 [44]362–1 yearPN/IV––3.1 (SD: 4.4)4 yearsPN/IV––4.1 (SD: 5.4)Pevny 2019 [45]2714.7 (n = 19)d12 weeksPN/IV11.9–2.8c (p < 0.001)15.9 (n = 17)d24 weeksPN/IV12.2–3.7c (p < 0.001)16.9 (n = 11)d52 weeksPN/IV10.6–6.3c (p < 0.001)16.5 (n = 8)d78 weeksPN/IV9.3–7.2c (p < 0.001)15.4 (n = 7)d104 weeksPN/IV8.6–6.8c (p < 0.001)Puello 2021 [47]189.9(95% CI: 6.7–13.2)3 months (n = 18)PN/IV5.6 (95% CI: 3.1–8.2)–4.3c6 months (n = 18)PN/IV4.6 (95% CI: 2.6–6.7)–5.3c1 year (n = 16)PN/IV5.6 (95% CI: 3.2–8.1)–4.3c2 years (n = 13)PN/IV4.7 (95% CI: 1.9–7.4)–5.2c3 years (n = 10)PN/IV4.8 (95% CI: 1.7–7.9)–5.1c5 years (n = 3)PN/IV0 (95% CI: 0–0)–9.9cSato 2023 [48]1615.8b(range: 7.7–49.0)4 weeksPN/IV11.6b (range: 0.0–42.0)–4.2b,c (p = 0.0031)8 weeks10.7b (range: 0.0–38.5)–5.1b,c (p = 0.0038)Schoeler 2018 [49]1412.2 (SD: 2.3)12 weeksIV11.5 (SEM: 2.2)–0.7c (p = 0.06)24 weeksIV10.9 (SEM: 2.3)–1.3c (p < 0.05)48 weeksIV7.8 (SEM: 1.8)–4.4c (p < 0.05)> 12 monthsIV2.5 (SEM: 0.9)–9.7c (p < 0.05)Siu 2024 [50]32PN: 7.0b (IQR: 3.0–7.0);IV: 7.0b (IQR: 3.0–7.0)–PN3.6b (IQR: 0.0–7.0)–3.5b,c (p < 0.01)IV3.0b (IQR: 0.0–7.0)–4.0b,c (p < 0.01)Solar 2021 [51]1712.1 (range: 8.1–16.1)4 weeksPN11.8 (range: 7.5–16.1)–0.3c8 weeksPN11.0 (range: 6.6–15.3)–1.1c (p = 0.046 vs week 4)12 weeksPN10.5 (range: 6.0–15.0)–1.6c (p = 0.020 vs week 8)16 weeksPN8.4 (range: 2.9–13.8)–3.7c (p = 0.007 vs week 12)20 weeksPN7.9 (range: 2.3–13.5)–4.2c (p = 0.022 vs week 16)24 weeksPN6.9 (range: 1.0–12.8)–5.2c (p = 0.057 vs week 20)Last follow-upPN4.1 (range: 0.1–8.0)–8.1c (p = 0.003 vs week 24; p = 0.001 vs baseline)Solar-Muñiz 2023 [52]1612.1 (SD: 4.1)12 weeksPN8.9 (SD: 3.6)–3.2c (p < 0.01)24 weeksPN5.4 (SD: 4.8)–6.7c (p < 0.01)Ukleja 2018 [53]67.7 (SD: 4.3)6 monthsPN/IV0.8c–6.9All applicable information was reported if it was available or could be calculated from source data. Values may have been rounded for consistency in reporting. Cells containing only dashes indicate that the information was not available and could not be calculated.CI, confidence interval; IQR, interquartile range; IV, intravenous fluids; PN, parenteral nutrition; PN/IV, parenteral nutrition and/or intravenous fluids; SD, standard deviation; SEM, standard error of the mean; vs, versus.aMean unless otherwise indicated.bMedian.cCalculated from source.dValues are for patients with corresponding follow-up data. PN/IV volume at baseline and follow-up. All applicable information was reported if it was available or could be calculated from source data. Values may have been rounded for consistency in reporting. Cells containing only dashes indicate that the information was not available and could not be calculated. CI, confidence interval; IQR, interquartile range; IV, intravenous fluids; PN, parenteral nutrition; PN/IV, parenteral nutrition and/or intravenous fluids; SD, standard deviation; SEM, standard error of the mean; vs, versus. Mean unless otherwise indicated. Median. Calculated from source. Values are for patients with corresponding follow-up data. Similar to infusion frequency, studies that included more than one follow-up time point generally showed greater reductions from baseline over time, although some fluctuations were observed at later time points. Across studies reporting PN/IV infusion volume, means/medians ranged from −1.4 to −6.9, −2.8 to −7.0, and −2.8 to −9.9 L/week, at 6, 12, and/or > 12 month follow-ups, respectively. No consistent patterns were observed in relation to cohort size. Enteral autonomy Twenty-one studies reported the percentage of patients who attained enteral autonomy with time points from 4 weeks up to 7 years (Table 4). Studies reported enteral autonomy with reference to PN/IV, PN or IV (see Table 4). The proportion of patients who attained enteral autonomy at the last time point reported for each study ranged from 10.5% (at up to 2 years; PN/IV and PN only), in a German multicenter study with a median treatment duration of approximately 1 year [45], to 100.0% at 1.5 years (PN, IV) and 5 years (PN/IV), in two US single-center studies, with a median teduglutide therapy length of 2.7 and 3.2 years, respectively [47], [53]. Table 4Proportions of patients attaining enteral autonomy.PublicationN who received teduglutideBaseline PN/IV volume, L/weekaFollow-upParameter assessedPatients attaining enteral autonomyn/N assessed%Blüthner 2023 [23]1713.9 (SD: 6.6)4.3 yearsbPN/IV4/1723.5Chapman 2023 [24]1010.8b2–4 yearsPN/IV3/1030.0PN onlyc3/1030.0Compher 2016 [25]712.5dNRPN2/728.6Daoud 2023 [26]3410.8b (IQR: 7.0–14.7)6 monthsPN/IV2/296.91 yearPN/IV5/26e19.2e1.5 yearsPN/IV9/27e33.3eDe Dreuille 2023[28]568.8b (IQR: 5.0–12.5)2.7 yearsb (IQR: 1.7–4.4 years)PN/IV20/5635.7Martin 2021 [42]317.5b (IQR: 3.5–15.0)1 yearPN/IV9/3129.0Gombošová 2024 [29]97.9 (SD: 3.9)f12 weeksPN/IV0/80.06 monthsPN/IV1/8e12.5e1 yearPN/IV4/7e57.1dGondolesi 2020 [31]8–4.4 yearsgPN6/875.0Solar 2021 [51]1712.1 (range: 8.1–16.1)Last follow-upPN7/1741.2Greif 2022 [32]5213.4 (SD: 7.5)3 monthsPN/IV0/44 h0.0 h6 monthsPN/IV2/44e,h4.5e,h1 yearPN/IV11/44e,h13.6e,hHarpain 2022 [33]1323.6 (SD: 6.9)24 weeksPN/IV6/1369.2Iyer 2023 [34]20––PN7/2035.0Joly 2020 [35]5411.2 (SD: 1.1)24 weeksPN/IV12/5223.1Kim 2024 [37]13–Up to 7 yearsPN/IV6/1346.2Kochar 2017 [38]139.0b (IQR: 7.0–14.0)f14 monthsbPN8/988.9IV6/1346.2Lam 2018 [39]189.9b (range: 2.7–30)10 monthsbPN/IV11/1861.1Maiz Jimenez 2023[41]3110.9 (range: 4.5–35.1)6 monthsPN/IV5/3116.11 yearPN/IV8/31e25.8e1.5 yearsPN/IV10/31e32.3e2 yearsPN/IV11/31e35.5ePevny 2019 [45]2713.7 (SD: 7.9)Up to 2 yearsPN/IV2/1910.5PN onlyc2/1910.5Puello 2021 [47]189.9 (95% CI: 6.7–13.2)3 monthsPN/IV3/1816.76 monthsPN/IV4/18e22.2e1 yearPN/IV3/16e18.8e2 yearsPN/IV4/13e30.8e3 yearsPN/IV3/10e30.0e5 yearsPN/IV3/3e100.0eSato 2023 [48]1615.8b (range: 7.7–49.0)4 weeksPN/IV1/166.326 weeksPN/IV2/16e12.5eSchoeler 2018 [49]1412.2 (SD: 2.3)15.7 monthsdPN/IV2/1414.3Siu 2024 [50]32PN: 7.0b (IQR: 3.0–7.0);IV: 7.0b (IQR: 3.0–7.0)–PN/IV8/3225.0Ukleja 2018 [53]67.7 (SD: 4.3)6 monthsPN3/475.0IV1/250.01.5 yearsPN4/4100.0IV2/2100.0All applicable information was reported if it was available or could be calculated from source data. Cells containing only dashes indicate that the information was not available and could not be calculated.CI, confidence interval; IQR, interquartile range; IV, intravenous fluids; NR, not reported; PN, parenteral nutrition; PN/IV, parenteral nutrition and/or intravenous fluids; SD, standard deviation.aMean unless otherwise indicated.bMedian.cPatients still required IV fluids.dCalculated from source.eData are cumulative.fReported for IV only.gMean follow-up time overall.hEstimated from data depicted in chart. Proportions of patients attaining enteral autonomy. All applicable information was reported if it was available or could be calculated from source data. Cells containing only dashes indicate that the information was not available and could not be calculated. CI, confidence interval; IQR, interquartile range; IV, intravenous fluids; NR, not reported; PN, parenteral nutrition; PN/IV, parenteral nutrition and/or intravenous fluids; SD, standard deviation. Mean unless otherwise indicated. Median. Patients still required IV fluids. Calculated from source. Data are cumulative. Reported for IV only. Mean follow-up time overall. Estimated from data depicted in chart. In general, the proportion of patients who attained enteral autonomy increased over time versus baseline within studies that reported more than one follow-up time point. Across studies reporting enteral autonomy in relation to PN/IV, the proportions of patients who attained enteral autonomy ranged from 4.5–22.2%, 13.6–57.1%, and 10.5–100%, at 6, 12, and/or > 12 month follow-ups, respectively. No consistent patterns were observed in relation to cohort size. Outcomes by bowel anatomy Seven studies reported effectiveness outcomes in relation to bowel anatomy (Supplementary Table S3). Five studies reported data from subgroups of patients with stomas versus those with CIC. Two studies reported data across three bowel anatomy subgroups, defined as patients with jejunostomy or ileostomy (Group 1), patients with at least 50% of CIC (Group 2), and patients with less than 50% colon or colostomy (Group 3). No consistent differences in outcomes were observed by bowel anatomy; larger PN/IV volume reductions were observed in patients with stomas compared with patients with CIC, although, in general, a greater proportion of patients with CIC attained enteral autonomy. Both patients with stomas and patients with CIC contribute to the overall efficacy outcomes. PN/IV infusion frequency by bowel anatomy Mean PN/IV infusion frequency was reduced by 2.5 days/week in patients with CIC and 2.3 days/week in patients with stomas at 18 months in a Canadian registry study of 34 patients (p value for CIC vs stomas not statistically significant) [26]. In a French multicenter study of 54 patients, mean PN/IV infusion frequency was reduced by 1.4 days/week in patients with jejunostomy or ileostomy (bowel anatomy Group 1), 1.6 days/week in patients with at least 50% of CIC (Group 2), and 3.0 days/week in patients with less than 50% colon or colostomy (Group 3; p value not reported) [35]. PN/IV volume by bowel anatomy In the Canadian registry study, median PN/IV volume was reduced by 2.5 L/week and 5.0 L/week in patients with CIC and with stomas, respectively, at 18 months (p value for CIC vs stomas not statistically significant) [26]. In a Japanese single-center study of 16 patients, median PN/IV volume was reduced by 2.1 L/week in patients with CIC (p = 0.37 vs baseline) and 6.6 L/week in patients with stomas (p = 0.009 vs baseline) at 8 weeks [48]. The French multicenter study of 54 patients observed a reduction in mean PN/IV volume by 6.7 L/week in bowel anatomy Group 1 (jejunostomy or ileostomy), 3.7 L/week in Group 2 (≥ 50% of CIC), and 8.5 L/week in Group 3 (< 50% colon or colostomy) at 24 weeks [35]. A German home-care service program study of 52 patients observed a reduction in median PN/IV volume of approximately 3.0 L/week in bowel anatomy Group 1 (p < 0.05 vs baseline), 1.5 L/week in Group 2 (p < 0.01 vs baseline), and 2.0 L/week in Group 3 (p value not significant vs baseline) at 12 months [32]. Enteral autonomy by bowel anatomy In the Canadian registry study, five of 15 patients (33.3%) with CIC and four of 19 patients (21.0%) with stomas attained enteral autonomy (p value for CIC vs stomas not statistically significant) [26]. In a US single-center case series, enteral autonomy was attained in two of three patients (66.7%) with CIC but in none of four patients (0.0%) with stomas (p value not reported) [25]. Another US single-center study found that enteral autonomy at 5 years was attained in three of nine patients (33.3%) with CIC and two of nine patients (22.2%) with stomas (p value not reported) [47]. A Spanish multicenter study found that enteral autonomy at a mean of 11.5 months was attained in six of 18 patients (33.3%) with CIC and five of 13 patients (38.5%) with stomas [41]. In the French multicenter study, at 24 weeks, enteral autonomy was attained in two of 19 patients (10.5%) in bowel anatomy Group 1, 10 of 33 patients (30.3%) in Group 2, and one of two patients (50.0%) in Group 3 (p = 0.04 for Groups 2 and 3 vs Group 1) [35]. HRQoL Four studies reported changes from baseline in HRQoL [23], [32], [33], [50]; all studies observed improvements from baseline with teduglutide therapy. A German single-center study assessed HRQoL among 17 patients with SBS-IF who received teduglutide for a median of 4.3 years, using the Short Bowel Syndrome Quality of Life Questionnaire (SBS-QoL) and the 36-item Short Form Health Survey (SF−36) [23]. SBS-QoL summary score decreased (improved) significantly during teduglutide treatment (mean change from baseline: –33.1 [p < 0.001]) [23]. For the SF−36, both the physical and mental component summary scores increased (improved) significantly during teduglutide treatment (mean change, physical: +5.3 [p = 0.011]; mental: +7.7 [p = 0.023]) [23]. Two studies assessed changes in sleep quality [32], [33]. The median (range) number of sleep disturbances per night decreased from 3.0 (0.0–7.0) at baseline, to 1.0 (0.0–10.0; p < 0.05 vs baseline), 1.5 (0.0–7.0; p value not significant), and 2.0 (0.0–8.0; p value not significant) at 3, 6, and 12 months, respectively, in a study of 52 patients with SBS-IF who received teduglutide in the German home-care service program study [32]. In a single-center study conducted in Austria (N = 13), the mean number of disease-associated sleep interruptions per night decreased significantly from 4.6 at baseline to 1.8 at 24 weeks (p = 0.002) and 1.4 at week 48 (p = 0.014) [33]. In a US single-center study that included 32 patients with SBS-IF and CD, 84.4% of study participants reported meaningful improvements in symptoms including increased energy levels, decreased stool frequency and output (lower proportion of patients with ≥ 3 bowel movements or ≥ 1.5 L ostomy output per day), or improved mood following teduglutide initiation (length of follow-up not reported; improvements not reported separately by item) [50]. Medication burden Changes in medication burden were assessed in one study [50]. In 32 patients with SBS-IF and CD, 90.6% of patients used at least one antidiarrheal medication at baseline, compared with 84.4% at follow-up (p = 0.16; length of follow-up not reported; antidiarrheal medication use defined as documentation of usage and active prescriptions as verified by chart review). The median number of unique antidiarrheal medications was 3.0 at baseline and 2.0 at follow-up (p < 0.01). Dose changes, interruptions, and discontinuations Seventeen studies reported on teduglutide dose changes, interruptions, and/or discontinuations (Supplementary Table S4). Dose reductions and/or interruptions (including injection interval lengthening) occurred in 5.9–58.8% of patients. The length of interruption was not consistently reported. Discontinuations were reported in 5.8–71.4% of patients across studies that reported such data. When reasons were reported, these included adverse events (AEs) and tolerability for dose reductions, interruptions, and discontinuations, and additionally were about lack of effectiveness, cost, impending surgery, and underlying comorbidities for discontinuations, including renal causes. Safety Safety outcomes were reported in 17 studies (Table 5). Most studies reported safety outcomes as the proportion of patients experiencing at least 1 event, whereas a small number of studies reported incidence rates per patient‑years for some outcomes (see Table 5 for details). The most frequently reported AEs included abdominal pain/cramping (2.9–50.0% of patients; 14 studies), nausea (7.7–35.3% of patients; 11 studies), injection-site reactions (3.8–42.9%; 5 studies), catheter-related sepsis or infection (7.7–92.0%; 6 studies), and stoma complications (7.7–100.0% of patients with stomas; 9 studies). Table 5Safety outcomes (% of patients).PublicationNaAbdominal pain/cramping, distension/flatulenceNausea, vomiting, dizziness, headachesCatheter-related sepsis or infectionDrug injection-site reactionsVolume overload, CHF, edemaStoma complicationsEnzyme valuesDeathOtherCompher 2016 [25]7Pain/cramping: 14.3Nausea/vomiting: 14.3–42.928.6Stoma enlargement: 66.7 (2/3 with stoma)–b14.3 (considered related to teduglutide: 0.0)Benign polyps: 28.6; cholecystitis: 28.6; copper deficiency after weaning from PN/IV: 14.3; intestinal obstruction/obstructive symptoms: 14.3; neoplasia: 0.0Daoud 2023 [26]34Pain/cramping: 2.9–––Hand swelling: 2.9–Laboratory values remained within normal limits2.9 (considered related to teduglutide: 0.0)Gallbladder disease: 11.8; nonspecific CEA: 2.9De Dreuille 2023[27]35c––––––––Polypoid lesions: 28.6Multinational SBS Registry (NCT01990040)Gondolesi 2023 [30]669Pain/cramping: 15.5–Vascular device infection: 15.4; device-related infection: 11.5––––7.3 (considered related to teduglutide: 0.1)Colorectal polyps: % not reported (incidence: 30.4/1000 PY); colorectal cancer: 0.0Joly 2023 [36]540––––––––New or worsening colorectal polyps: 3.0 (incidence 13.4/1000 PY); new or worsening diagnosis of malignancy: % not reported (incidence 17.4/1000 PY)Greif 2022 [32]52Abdominal pain: 26.9; distension/flatulence: 25.0Nausea: 13.5; vomiting: 5.8; headache: 9.6; dizziness: 5.8Catheter-related systemic infection: 32.7; central line dislocation/occlusion or outer infection: 7.73.8Edema: 7.7GI stoma complications: 9.6Elevated renal parameters: 3.8–Appetite disorders: 5.8; asthenia: 5.8; common cold/upper respiratory infection: 11.5; diarrhea: 3.8; gastroenteritis: 3.8; hot flush/night sweats: 7.7; hypertension: 7.7; kidney stone passage: 3.8; obstipation: 3.8; peripheral embolism and thrombosis: 3.8; urinary tract infection: 7.7; weight loss: 7.7Harpain 2022 [33]13Abdominal pain: 23.1; abdominal distension/bloating: 7.7Nausea/vomiting: 30.8; vertigo: 15.4; headache: 7.7CLABSI with subsequent catheter removal: 92–Clinical signs of volume overload: 30.8––7.7 (cause: respiratory failure due to systemic scleroderma)Upper respiratory infections: 7.7; cholecystitis: 7.7; fatigue: 23.1; diarrhea: 15.4; constipation: 7.7; joint/muscle pain: 15.4; heavy sweating: 15.4; polyps, colorectal tumorigenesis or carcinogenesis: 0Joly 2020 [35]54–d–––––––Acute cholecystitis requiring cholecystectomy: 1.9Kim 2024 [37]13Abdominal discomfort: 38.5Nausea: 7.7; dizziness: 7.7; headache: 7.7–––Stoma enlargement: 7.7Elevation of amylase or lipase: 72.7 (8/11 patients with serum values)7.7 (considered related to teduglutide: 0.0)Cholecystitis: 7.7; increased vaginal discharge: 7.7; insomnia: 7.7; lung mass: 7.7; pulmonary nodule: 53.8 (n = 7 [pre-existing, n = 4]); weight gain: 7.7Kochar 2017 [38]13Abdominal pain/cramping: 15.4Nausea: 7.7Catheter-related sepsis: 30.8–––Elevation of amylase or lipase: 7.7–Intestinal obstruction/obstructive symptoms: 7.7; pancreatitis: 7.7Lam 2018 [39]18Abdominal pain: 33.3; abdominal pain and flatulence: 11.1Nausea: 22.2–5.6–Stoma enlargement: 100 (3/3 with stoma)–11.1 (considered related to teduglutide: 0.0)Abnormal colonoscopies: 33.3 (4 of 12 colonoscopies conducted: cecal polyps consistent with tubular adenomas; nonspecific enteritis; Crohn’s ileitis; dilated bowel with nonspecific colitis)Loutfy 2022 [40]170Abdominal pain/cramping: 41.2Nausea: 23.5Catheter sepsis: 11.8––11.8––Colon polyps: 5.9; intestinal obstruction: 17.6Pevny 2019 [45]27Abdominal pain: 33.3; abdominal distension including flatulence: 40.7Nausea: 29.6; headache: 18.5–14.8Clinical signs of volume overload: 22.2Stoma nipple hypertrophy: 50.0––Colorectal polyp or adenoma growth: 0.0; respiratory infections: 18.5Puello 2021 [47]18Abdominal pain: 16.7; abdominal cramping: 5.6–––Volume overload: 5.6; lower extremity edema: 11.1Stoma enlargement: 11.1–11.1 (considered related to teduglutide: 0.0)Alterations in taste: 5.6Sato 2023 [48]16Abdominal pain: 31.3; abdominal distension: 12.5Nausea: 12.5Catheter sepsis: 31.3–Edema: 25.0GI stoma complication: 43.7No significant changes in laboratory values for albumin, eGFR, hematocrit, CRP–Upper respiratory infection: 6.3Schoeler 2018 [49]14–e–e––e––e––New polyps: 0.0Solar 2021 [51]17Abdominal pain: 47.1; abdominal distension: 64.7Nausea: 35.3––––––Arthralgia: 11.8; constipation: 5.9; renal failure secondary to rapid progressive glomerulonephritis: 5.9; skin rash: 11.8Ukleja 2018 [53]6Abdominal pain/discomfort: 50.0; flatulence: 83.3Nausea/vomiting: 33.3; dizziness/headache: 0.0–Injection site bruising: 16.7; injection site erythema: 0.0Peripheral edema: 16.7; CHF: 16.750.0–16.7Arthralgia: 16.7; back pain: 33.3; breast pain: 16.7; dehydration: 0.0; muscle cramp: 0.0; nasopharyngitis/sinusitis: 0.0; renal and urinary disorders: 16.7; skin and subcutaneous disorders: 0.0; small bowel obstruction: 16.7; swelling: 50.0All applicable information was reported if available or could be calculated from source data. Data are reported as % of patients with events unless otherwise specified. Cells containing only dashes indicate that the information was not reported.CEA, carcinoembryonic antigen; CHF, congestive heart failure; CLABSI, central line-associated bloodstream infection; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; GI, gastrointestinal; PN/IV, parenteral nutrition and/or intravenous fluids; PY, patient-year(s); SBS, short bowel syndrome.aNumber of patients who received teduglutide.bNot reported consistently.cOnly patients who underwent follow-up endoscopy were included in the study.dMain side effect was abdominal pain (n or % not reported).eAbdominal distension or bloating, nausea, injection site inflammation, and ostomy nipple growth were reported as adverse events, but corresponding numbers were not reported. Safety outcomes (% of patients). All applicable information was reported if available or could be calculated from source data. Data are reported as % of patients with events unless otherwise specified. Cells containing only dashes indicate that the information was not reported. CEA, carcinoembryonic antigen; CHF, congestive heart failure; CLABSI, central line-associated bloodstream infection; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; GI, gastrointestinal; PN/IV, parenteral nutrition and/or intravenous fluids; PY, patient-year(s); SBS, short bowel syndrome. Number of patients who received teduglutide. Not reported consistently. Only patients who underwent follow-up endoscopy were included in the study. Main side effect was abdominal pain (n or % not reported). Abdominal distension or bloating, nausea, injection site inflammation, and ostomy nipple growth were reported as adverse events, but corresponding numbers were not reported. Five studies reported changes in clinical laboratory values. Laboratory values remained within normal limits in the Canadian registry study [26], and no significant changes in laboratory values were observed in the Japanese single-center study [48]. Elevated renal parameters were observed in 3.8% of patients in the German home-care service program study [32]. Elevated amylase or lipase levels were reported in 72.7% of patients in a US single-center study (onset of event 1–54 months after starting teduglutide therapy [37]) and in 7.7% of patients in a US multicenter study (onset of event not reported; median teduglutide therapy duration in study: 1 year) [38]. In total, eight publications reported on deaths. Five studies reported on colorectal carcinogenesis. No cases of colorectal cancer were observed in one publication from the large, multinational SBS Registry study, which included data from 669 teduglutide-treated patients with a mean treatment exposure of 37.8 months [30]. Of the remaining four studies, one study observed a single tubular adenoma among five patients (20.0%) who underwent follow-up colonoscopies [39], and three studies observed no cases (0.0%) of colorectal carcinogenesis [33], [36], [45]. Eight studies reported on colorectal polyps. The incidence of new or worsening colorectal polyps in the SBS Registry study was 30.4 per 1000 patient-years at the latest data cut-off available at the time of the present SLR [30]. Across four further studies that observed polyps during follow-up colonoscopies, the proportions of patients with polyps were 5.9% (10/170 patients) [40], 8.3% (1/12 patients who underwent colonoscopy) [39], 28.6% (2/7 patients) [25], and 28.6% (10/35; small bowel polyp, n = 8; colonic polyp, n = 2) [27]. Three studies found no new polyps (0.0%) during follow-up colonoscopies [33], [45], [49]. Risk of bias Low to moderate within-study risk of bias was observed for confounding bias, selection bias, intervention biases, outcome measurement bias, and reporting bias for 20 of the 26 included studies, resulting in an overall moderate risk of bias (Supplementary Table S5). In three studies, the risk of overall bias was high, and a further three studies did not report sufficient information for the overall risk of bias to be assessed. Discussion This SLR reviewed the effectiveness, including HRQoL, and safety of teduglutide, the first approved intestinotrophic therapy for SBS-IF [54], in adult patients with SBS-IF in clinical practice. Using a comprehensive search to capture a range of outcomes, we summarize 10 years of real-world data from 26 studies conducted across multiple locations and published since 2016. The heterogeneous nature of the included studies should be kept in mind when interpreting the evidence, in particular when grouping results across studies. Enteral autonomy is considered the ideal outcome of intestinal rehabilitation [55]. This was attained by at least some patients in all studies reporting on enteral autonomy. No clear trend was observed between baseline characteristics and attainment of enteral autonomy, although no formal statistical analysis was conducted within the present study. Despite being the ultimate goal, patients consider having at least some reduction in frequency or duration of PN/IV to be of great importance [56], highlighting the value of PN/IV reduction as a standalone target. Additionally, across infusion frequency, infusion volume, and enteral autonomy, studies reporting more than one follow-up time point generally showed greater improvements over time compared with baseline. No consistent patterns were observed in relation to study size. Teduglutide showed effectiveness across anatomic groups. In line with our findings, a previous SLR and meta-analysis of teduglutide in SBS within observational and randomized clinical trials concluded that the presence of CIC was a negative predictor for response (≥ 20% reduction in parenteral support volume) but a positive predictor for enteral autonomy [17]. Furthermore, clinical trial data show inconsistent trends in response by bowel anatomy. Several clinical trial publications suggested that patients with CIC may have a greater response or be more likely to attain enteral autonomy than those without [57], [58], [59], [60]; four concluded the opposite [11], [61], [62], [63]. Time to response is generally longer in patients with CIC than in those without [12], [62], [63], [64]. These variations may be due to patient- and center-specific factors, such as remaining bowel health, patient diet and lifestyle, and collective efficacy of ancillary therapies. Of the studies reporting teduglutide dose changes, interruptions, and/or discontinuations, commonly reported reasons included adverse effects of treatment, with renal causes also commonly mentioned. A previous analysis of AE reports from the Food and Drug Administration Adverse Event Reporting System (FAERS) presents a median time to occurrence of AEs of 393 days in patients who received teduglutide in real-world clinical practice, with gastrointestinal disorders being the most frequently reported [65]. Although valuable as part of post-marketing surveillance, FAERS is a spontaneous reporting system that has inherent limitations, such as a lack of information on the incidence of AEs, risk of duplications and no verification of reported AEs or their causes [66]. All four studies capturing HRQoL showed improvements with teduglutide, although SF−36 scores remained numerically lower than for healthy individuals [67]; only one of these studies used validated patient-reported outcome instruments (SBS-QoL, validated for use in patients with SBS, and SF−36). Findings for HRQoL were encouraging but based on limited data. Confirmation in additional studies using validated instruments is warranted. Considering the potential impact of SBS-IF on HRQoL [68], [69], it is surprising that HRQoL outcomes are not reported more frequently in the literature, and thus, this is a potential area for future research [70]. Antidiarrheal agents are frequently used in the management of patients with SBS-IF, with such treatments contributing to the potentially already substantial daily pill burden [71], [72]. One study reported a reduction from baseline in antidiarrheal treatment. Outcomes such as this may be considered a proxy for improved stool-related outcomes in patients with SBS-IF, who frequently experience diarrhea [73]. The risk for colorectal cancer may be impacted by age [74], etiology of SBS (e.g., inflammatory bowel disease) [75], and length of remaining colon. No cases of colorectal cancer were observed during a mean teduglutide exposure of 37.8 months during the publications identified reporting on the large, multinational SBS Registry. The incidence of new or worsening colorectal polyps was 30.4 per 1000 patient-years. The SBS Registry study included a comparator group of patients with SBS-IF who had never received teduglutide; this group had an incidence of new or worsening colorectal polyps of 4.5 per 1000 patient-years [30]. The study did not report relation to treatment. The incidence of colonoscopies was 182.3 and 64.6 per 1000 patient-years in the teduglutide-treated and comparator groups, respectively [30]. The higher rate of colonoscopies, potentially as a result of product labeling recommendations [76], may have contributed to the higher rate of polyp detection in patients who received teduglutide. Since the present literature review was conducted, a total of four colorectal cancer events have been reported; three in two patients who had received teduglutide, and one in one patient who had never received teduglutide. All events were considered to be not related to teduglutide [77]. It is important to note that these findings should be interpreted in the context of potential surveillance bias since patients treated with teduglutide are more likely to undergo endoscopic monitoring than untreated patients. The present SLR provides insights into teduglutide treatment in clinical practice. A key strength is its holistic overview across 26 studies. Strengths of the evidence include the well-defined baseline and objectively measurable effectiveness parameters. At review level, strengths include the broad, systematic literature search and inclusion of congress abstracts to capture the latest real-world data. Two previous systematic reviews of teduglutide effectiveness in clinical practice showed treatment effects by meta-analysis [17], [18]. One, conducted in 2020, included seven real-world studies [18]; the other, conducted in 2021, included six real-world studies and four randomized clinical trials and extension studies [17]. The latter did not observe a significant difference between randomized clinical trials and observational studies in response rate to teduglutide. The present SLR expanded on the findings from these previous reviews. A limitation of this SLR is risk of bias in observational studies, which were not designed to measure treatment effect. Most studies had low to moderate risk of bias across ROBINS-I items, with a moderate within-study bias overall. Such bias is distinct from issues of generalizability or applicability [21]. Several studies included overlapping patient data and were either grouped or noted accordingly; however, unidentified overlap may exist, including the possible involvement of patients in the SBS Registry (approximately 700 patients at the time of data extraction) in smaller studies. A limitation inherent to real-world studies, compared with clinical trials, is that some outcomes (e.g., laboratory assessment of enzyme levels) were less well reported. Another limitation is the heterogeneity in outcome definitions and follow-up time points reported across studies, limiting the ability to analyze data across studies. Finally, the impacts of follow-up upper gastrointestinal endoscopy (or alternate imaging) in addition to colonoscopy, as recommended in the recently updated product labeling [76], deserve further exploration. Conclusion In conclusion, this systematic review of real-world data supports the effectiveness and safety of teduglutide in treating SBS-IF in clinical practice, in terms of reducing PN/IV dependence and improving HRQoL, while maintaining an acceptable safety profile. Heterogeneous follow-up and outcome definitions limited comparisons across studies. The findings support a real-world benefit of teduglutide for patients with SBS-IF. Future studies should evaluate the impact of teduglutide on less well-reported outcomes such as HRQoL. CRediT authorship contribution statement Kishore Iyer: Writing – review & editing, Validation, Methodology, Conceptualization. Pradeep Nazarey: Writing – review & editing, Methodology, Conceptualization. Anja Becher: Writing – review & editing, Methodology, Investigation, Data curation. Shirley C. Paski: Writing – review & editing, Validation, Methodology, Conceptualization. Patient's/ Guardian's consent Not applicable. Ethical statement This work did not directly involve human participants and includes a report of previously published data; as such, ethical permissions were not required. Funding Support for this systematic review study was provided by PharmaGenesis Cardiff, with the financial support of Takeda Pharmaceuticals U.S.A., Inc. Medical writing assistance for the manuscript was provided by Liv Hayward, PhD, of PharmaGenesis Cardiff, Cardiff, UK, and was funded by Takeda Pharmaceuticals U.S.A., Inc., in accordance with Good Publication Practice (GPP 2022) guidelines (www.ismpp.org/gpp−2022). Declaration of Competing Interest Shirley C. Paski has received research funding from Takeda Pharmaceuticals U.S.A., Inc.; and has acted as medical adviser for Nutrishare (USA). Anja Becher is a contracted employee of PharmaGenesis Cardiff, Cardiff, UK, which has received payment from Takeda Pharmaceuticals U.S.A., Inc., for performing the systematic review study. Pradeep Nazarey was an employee and shareholder of Takeda Pharmaceuticals U.S.A., Inc., the manufacturer of teduglutide, at the time the current research was conducted; and is a current employee of Sanofi AG. Kishore Iyer has received research funding from Takeda Pharmaceuticals U.S.A., Inc., and VectivBio (Switzerland) – now Ironwood Pharmaceuticals (USA); and is a scientific adviser to Northsea Therapeutics (Netherlands), and Ironwood Pharmaceuticals. Acknowledgments Screening of the systematic literature search results and selection of the relevant literature were conducted independently by Anja Becher, PhD (co-author), and Liv Hayward, PhD, of PharmaGenesis Cardiff, Cardiff, UK. Data extraction was conducted by A Becher and cross-checked against the source data by L Hayward in a single-blind approach. The authors acknowledge Bram Raphael, MD, for his contribution. Footnotes Supplementary data associated with this article can be found in the online version at doi:10.1016/j.intf.2026.100387. Supplementary material Supplementary material References Associated Data Supplementary Materials Supplementary material